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Background: Aerobic glycolysis rate is higher in breast cancer tissues than adjacent normal tissues which
providethe ATP, lactate and anabolic precursors required for tumourgenesis and metastasis. Lactate dehydrogenase
(LDH) is a critical enzyme during aerobic glycolysis as it is typically responsible for the production of lactate and
regeneration of NAD+, which allows for the continued functioning of glycolysis even in the absence of oxygen.
LDH has been found to be highly expressed in breast tumors. Enzyme kinetic characteristics is related to
environmentinvolving the enzyme, and tumor microenvironment has distinct features relative to adjacent normal
tissues, thus we hypothesized that LDH should have different kinetic characteristics in breast tumors compared to
normal breast tissues.
Methods: LDH was partially purifiedfrom human breast tumors and normal tissues, which were obtained directly
from operating room. TheMichaelis-Menten constant (Km), maximum velocity (Vmax), activation energy (Ea) and
enzyme efficiency in breast tumors and normal tissueswere determined.
Results: It was found that tumor LDH affinity in forward reaction was the same as normal LDH but Vmax of
cancerous LDH was higher relative to normal LDH. In reverse reaction, affinity of tumor LDH for lactate and NAD+
was lower than normal LDH, also enzyme efficiency for lactate and NAD+ was higher in normal samples. The Ea of
reverse reaction was higher in cancerous tissues.
Conclusions: It was concluded that thelow LDH affinity for lactate and NAD+ is a valuable tool for preserving
lactate by cancer cells. We also conclude that increasing of LDH affinity may be a valid molecular target to abolish
lactate dependent tumor growth and kinetic characteristics of LDH could be a novel diagnostic parameter for
human breast cancer.
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Excessive growth is an important characteristic of cancer
cells. One of the main distinguishing features between
the normalcells and cancer cells is in their intermediary
metabolism [1]. Glycolysis and oxidative phosphorylation
are two major metabolism pathways for producing ATP in
mammalian cells [2]. Although oxidative phosphorylation
produces higher ATP from one mole of glucose when
compared to glycolysis, many questions remain about the
efficiency of these pathways for support of excessive
growth in cancer cells. According to the basic economic
law of supply and demand, oxidative phosphorylation in* Correspondence: siavash668@yahoo.com
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unless otherwise stated.normal cells is more efficient than glycolysis, but this does
not apply to cancer cells. Cancer cells mainly generate
ATP through glycolysis even in the presence of normal
oxygen pressure [3]. Conversion of glucose to lactic acid
in the presence of oxygen is known as aerobic glycolysis
or the Warburg effect. Increased glycolysis is mostly
observed in cancer cells. This bioenergetics and meta-
bolic feature not only permits cancer cells to survive
under adverse conditions such as hypoxia, but also
enables their proliferation, invasion and subsequent
distant metastasis. This condition alters cellular micro-
environment and makes it toxic for other cells, but has
no harmful effect on cancer cells [4]. High glycolysis
results in environmental acidosis that facilitates inva-
sion of cancer cells through destruction of adjacentntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinico-pathological characteristics of the
examined breast cancer patients
Clinical characteristics Grade % of patients




Histopathological grade 1 grade 14.28
2 grade 57.14
3 grade 28.57
Cellular characteristics Ductal carcinoma invasive 86.66
Ductal carcinoma in situ 13.33
Tumor size 2.1–3.0 13.33
>3.1 86.66
Auxillary lymph nodes status Metastasis negative 33.33
Metastasis positive 66.66
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matrix and promotion of angiogenesis [5].
The inhibition of Warburg effect may be used to at-
tenuate the growth advantages of cancer cells; however,
its precise molecular mechanisms are not completely
understood. Different mechanisms have been described
for glycolysis alteration in cancer cells [6,7]. One possi-
blereason for this bioenergetics alteration is the release
of various enzyme activators or inhibitors, which can
change the kinetic properties of enzymes involved in
glucose metabolism. Environmental parameters like pH,
temperature, or nutrient availability can influence en-
zyme activities and characteristics via transcriptional,
posttranscriptional, posttranslational, or allosteric regula-
tions. Slight attention has been paid to alteration of enzyme
kinetic in tumor environment, which can change intrinsic
characteristics of enzymes and metabolic pathways.
LDH is the final enzyme in glycolysis pathway that cat-
alyzes interconversion of pyruvate and lactate and it also
regenerates NAD+, which isnecessary for continued high
glycolysis rate in cancer cells. The gene expression and
activity of LDH (in pyruvate reducing direction) is
higher in breast cancer cells relative to adjacent normal
cells. Also, upregulation of the LDH-A in clinical tu-
mors is often associated with disease progression and
poor prognosis [8-12]. Interestingly, clinical evaluation
of LDH-B could be a predictive marker of response for
patients with breast cancer receiving neoadjuvant
chemotherapy [13]. Given the findings, it is concluded
that LDH is animportant effector of glucose metabol-
ism in cancer cells and can affect tumorigenesis and
metastasis. Possible changes in kinetic parameters of
LDH with attention to different tumor microenviron-
mentshave not been studied in cancer tissue. The aim of
the current study was to compare the kinetic properties




Seventeen human breast tumor samples were obtained
from Apadana Hospital during the surgery. Normal tis-
sues away from the tumor were included as controls.
Two independent expert pathologists from the path-
ology laboratory of Apadana hospital carried out the
pathological tumor and control tissue examination. The
clinical and histological characteristics of breast cancer
patients are shown in Table 1. Samples were immedi-
ately preserved in liquid nitrogen, transported to the la-
boratory, and stored at −80°C. The study was approved
by the ethics committee from Jundishapour Medical
University of Ahvaz and conducted according to the
Guide for Human study by the National Academy of
Sciences (National Institutes of Health), and informedconsent was obtained from all patients involved in this
study.
Sample preparation and LDH partial purification
Frozen tumors and normal tissues were homogenized
(1:5 w:v) in ice cold homogenization buffer (20
mMTris–HCl, pH 8.0, 10 mM 2-mercaptoethanol, 10%
v:v glycerol, 2 mM EDTA, 2 mM EGTA, and 20 mM β-
glycerophosphate) and a few crystals of phenylmethyl-
sulphonyl fluoride (PMSF) were added at the time of
homogenization. Samples were homogenized using a
Miccra homogenizer (Miccra, Germany), centrifuged
for 30 min at 13,500 g at 4°C and the supernatant was
decanted and held on ice until use. Low molecular
weight metabolites and ions were removed from the
supernatant by Sephadex G25 columns (1 × 5 cm) (Sigma,
Germany) that had been equilibrated in homogenizing
buffer [14].
LDH partial purification began with the preparation of
a DEAE-Sephasex column (1.5 × 10 cm) that was equili-
brated in assay buffer (20 mM Tris–HCl, pH 8). Follow-
ing equilibration, approximately 1.5 mL of crude extract
was placed on top of the column. The column was then
washed with 30 mL of assay buffer to remove any un-
bound proteins like LDH.
Additional experiments required a much pure LDH
sample, and therefore the top peak activity fractions
from the DEAE-Sephadex column were combined and
chromatographed on a Blue Sepharose CL-6B column
(1.5 × 10 cm) pre-equilibrated in homogenization buffer.
Following equilibration, the column was then washed with
50 mL of homogenization buffer to remove any unbound
proteins. A linear salt gradient of 0–2 M KCl was then ap-
plied to the column for the elution of LDH. Top activity
fractions were then pooled and held at 4°C until use. This
Table 2 Purification scheme for LDH in cancerous breast samples
Purification step Total protein (mg) Total activity (U) Specific activity (U/mg) Fold purification % yield
Supernatant 15 5.1 0.3 - -
DEAE-Sephadex 3.6 2.7 0.7 2.3 52
Blue Sepharose CL-6B 0.2 0.73 3.6 12 14
Talaiezadeh et al. Cancer Cell International  (2015) 15:19 Page 3 of 9sample was used for subsequent kinetic characterization
of LDH [14].
Enzyme assay and kinetic parameters
LDH activity was measured in the presence of pyruvate
with NADH as substrate for forward reaction and lactate
with NAD+ as substrate for reverse reaction. The lowest
saturating concentration of each substrate, which simul-
taneously showed maximum velocity, constant rate of
product formation and linear regressions of activities for
serial dilutions of enzyme, was assigned as optimum
substrate concentration.
Reactions were initiated by adding 10 μl of purified en-
zyme to a 200 μl total reaction volume by using 20 mM
Tris–HCl buffer pH 8, in the microplate well. Activity
was monitored at 340 nm for checking the conversion of
NADH to NAD+ (or vice versa) by using a Biotech
Powerwave X2s microplate reader (Biotech, USA) and
Gen5 software version 2.0 (USA) (kinetic mode, reading
interval = 39 s). The enzyme activity was expressed as
nmoles of pyruvate or lactate formed/min for reverse
and forward reactions, respectively.
Data were analyzed using microplate analysis (MPA)
and kinetics programs 3.51 [15,16]. Kinetics 3.51 computer
program fitted data through a nonlinear least squares re-
gression for determination of Km (substrate concentration
giving half-maximal activity; Michaelis-Menten constant)
and Vmax (maximum velocity) values.
The Km pyruvate was determined at 0.5 mM NADH
and pyruvate concentrations ranged from 0.05 mM to
2.15 mM. The Km NADH was determined at 1.5 mM
pyruvate and NADH concentrations ranged from 0.1 to
0.95 mM. In normal tissues, the Km lactate was deter-
mined at 3 mM NAD+ and lactate concentrations ranged
from 5–115 mM, while the Km NAD
+ was determined at
90 mM lactate and NAD+ concentrations ranged from
0.25 to 8.5 mM. In tumor samples, the Km lactate was de-
termined at 5 mM NAD+ and lactate concentrations
ranged from 10–325 mM while the Km NAD+ was deter-
mined at 250 mM lactate and NAD+ concentrationsTable 3 Purification scheme for LDH in normal breast sample
Purification step Total protein (mg) Total activity (U)
Supernatant 8.5 2.4
DEAE-Sephadex 1.9 1.35
Blue Sepharose CL-6B 0.18 0.42ranged from 0.5 to 9.5 mM. All assayswererun in 0.2 M
Tris-HCl buffer, pH 8.0. All reactions were done in tripli-
cate. The Km and Vmax were calculated from the mean of
three separate series of determinations. Total protein con-
tent was measured using Bradford method and bovine
serum albumin as standard.
Given the possible existence of endogenous NADH to
NAD+ interconvesrion (i.e. NADH oxidation by com-
plex І activity) in partial purified samples, the NADH to
NAD+interconversion was surveyed in each sample to
eliminate the possible existence of its effect. This
interconversion was determined by adding the NADH
(0.5-1 mM) or NAD+ (3–5 mM) in Blue Sepharose
purified samples and monitoring the change in absorb-
ance at 340 nm.
Calculation of activation energy
Maximal LDH activity was determined at 5°C incre-
ments starting from 18°C and ending at 42°C. The
reaction temperature was set by using incubator of
Biotech Powerwave X2s microplate reader. Substrates
concentrations were as follow: 1.5 mM pyruvate and
0.5 mM NADH in forward reaction, 90 mM lactate
and 3 mM NAD+ in reverse reaction for normal tis-
sues, 250 mM lactate and 5 mM NAD+ in reverse
reaction for tumor tissues. Arrhenius plots were con-
structed from these experiments and the Ea was
calculated.
Calculation of enzyme efficiency
To determine enzyme efficiency the Vmax/Km lactate and
Vmax/Km NAD
+ ratio were calculated for tumor and nor-
mal samples.
Statistical analysis
Data were expressed as mean ± SEM from independent
determinations on separate preparations of enzyme. Data
were analyzed using Student’s t-test. The level of signifi-
cance for all tests was set at p < 0.05.s




Table 4 Kinetic parameters of LDH in forward reaction
from breast tumors (n =17) and normal tissues (n = 17)
Tumor Normal
S 0.5 pyruvate (mM) 0.78 ± 0.07 0.63 ± 0.03
S 0.5 NADH (mM) 0.3 ± 0.01 0.33 ± 0.01
Vmax pyruvate (mU/mg protein) 4034 ± 348* 1747 ± 68
Vmax NADH (mU/mg protein) 2788 ± 111* 1370 ± 52
Ea (kcal/mol) 51 ± 4.1 41 ± 5.6
Assays were conducted at 25°C and data are presented as means ± SEM, n = 3
independent determinations on each of 17 tumor and normal samples.
*Significant difference in each row at p < 0.05.
Talaiezadeh et al. Cancer Cell International  (2015) 15:19 Page 4 of 9Results
LDH partial purification
The purification procedure employed was proven to be
efficient; a typical purification experiment is summarized
in Tables 2 and 3. DEAE–G50 Sephadex chromatog-
raphy resolved one peak activity of LDH from tumor
and normal breast samples and Blue Sepharose chroma-
tography determined one peak activity of LDH from top
fractions of DEAE-G50 chromatography from both the
tumor and normal samples. Peak activity of LDH was
consistently eluted in Blue Sepharose at 0.5-1.3 M KCl
from both tumor and normal breast specimens. The elu-
tion patterns of LDH showed no significant difference
between tumor and normal breast tissues (Figure 1).
Optimization of experimental conditions
Optimum assay conditions for LDH in forward reaction
were 1.5 mM pyruvate and 0.5 mM NADH in both tu-
mors and normal tissues. In the reverse reaction, optimal
conditions were different in normal and tumor samples.
Optimum conditions in normal samples were 90 mM
lactate and 3 mM NAD+ while in tumor samples they-
were 250 mM lactate and 5 mM NAD+. It should be
noted that there is no NADH to NAD+ interconversion
activity (or vice versa) in partially purified samples.
Kinetic properties of LDH in forward reaction
The maximal activity of cancerous-LDH (C-LDH) for
lactate formation (4034 ± 348 mU/mg protein for pyru-
vate and 2788 ± 111 mU/mg protein for NADH) was
higher than the values in normal tissues (N-LDH)
(1747 ± 68 mU/mg protein for pyruvate and1370 ±
52 mU/mg protein for NADH) (Table 4). The enzyme
in forward reaction in both tissues displayed sigmoidal
kinetics with respect to pyruvate and NADH (Figures 2Figure 1 Blue Sepharose CL-6B elution profiles for LDH activity from
relative to the highest activity fraction. (a) and (b) LDH elution profiles from
Blue Sepharose CL-6B, respectively. ●, LDH activity; ○, KCl concentration.and 3). Hill coefficients for pyruvate and NADH in tu-
mors were 1.36 ± 0.12 and 2.8 ± 0.28, and in normal
samples were 1.36 ± 0.07 and 2.5 ± 0.19 respectively.
However, the S0.5 of pyruvate (0.78 ± 0.12 mM for
tumor and 0.63 ± 0.04 mM for normal) and NADH
(0.3 ± 0.01 mM for tumor and 0.33 ± 0.01 mM for nor-
mal) were not significantly different between normal
and cancerous tissues (Table 4).Kinetic properties of LDH in reverse reaction
The maximal activity of LDH with respect to lactate
(630 ± 4.9 mU/mg protein for tumor and 602 ± 2.2 mU/mg
protein for normal) and NAD+ (1282 ± 71.24 mU/mg
protein for tumor and 1237 ± 21.2 mU/mg protein for
normal) were not significantly different between normal
and cancerous tissues (Table 5).
The Km lactate of N-LDH (10.73 ± 0.54 mM) was
significantly lower than that of C-LDH (21.78 ±
1.07 mM) (p < 0.05) (Table 4). The Km NAD
+ was sig-
nificantly lower in normal tissues (0.5 ± 0.06 mM)
than that in tumor tissues (0.99 ± 0.2 mM) (p < 0.05)
(Figures 4 and 5).tumor and normal human breast tissues. Activities are expressed
tumor and normal breast top fractions of DEAE–G50 Sephadex on
Figure 2 Initial velocity (vi) versus substrate concentration of (a) Pyruvate: 0.05-2.15 mM and (b) NADH: 0.1-0.95 mM for LDH in partial
purified of breast cancer samples (n =17) in forward reaction. Data are presented as means ± SEM, n = 3 independent determinations on
separate enzyme samples.
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Ea values of C-LDHL and N-LDH are shown in
Table 4 and 5. The Ea in forward reaction was not
significantly different between thetwo tissues (51 ± 4.1
Kcal/mol for tumor and 41 ± 5.6 Kcal/mol for normal
tissue), while the Ea in reverse reaction was significantly
higher in cancerous tissues (39.12 ± 4.6 Kcal/mol) com-
pared to that in normal tissues (16.78 ± 1.7 Kcal/mol)
(p < 0.05).
Enzyme efficiency
Enzyme efficiency related to lactate in normal tissues
was two-fold higher than tumor samples (56.1 ± 2.4 and
28.92 ± 1.3 mU/mg/mM, respectively). In the case ofFigure 3 Initial velocity (vi) versus substrate concentration of (a) Pyru
purified breast normal tissues (n =17) in forward reaction. Data are pr
separate enzyme samples.NAD+, enzyme efficiency in normal tissues was about
two-fold higher than tumor samples (2474 ± 8.1 and
1294.94 ± 6.7 mU/mg/mM, respectively) (Table 6).
Discussion
Glycolysis pathway has a different pattern in cancer
when compared to normal cells because expression, struc-
ture and activity of some enzymes (e.g. pyruvate kinase)
and some important master regulators (e.g. HIF-1, myc)
are diverse [17,18]. The knowledge of glycolysis multipli-
city is vital to comprehend the nature of the cancer cells
in order to obliterate them because the best way to des-
troy an army is to identify all the parts of it and point out
its weaker part as the Achilles’ heel.vate: 0.05-2.15 mM and (b) NADH: 0.1-0.95 mM for LDH in partial
esented as means ± SEM, n = 3 independent determinations on
Table 5 Kinetic parameters of LDH in reverse reaction
from breast tumors (n = 17) and normal tissues (n = 17)
Tumor Normal
Km lactate (mM) 21.78 ± 1.07* 10.73 ± 0.54
Km NAD
+ (mM) 0.99 ± 0.05* 0.50 ± 0.06
Vmax lactate (mU/mg protein) 630 ± 4.9* 602.2 ± 2.2
Vmax NAD
+ (mU/mg protein) 1282 ± 71.24* 1237 ± 21.2
Ea (kcal/mol) 39.12 ± 4.6* 16.78 ± 1.7
Assays were conducted at 25°C and data are presented as means ± SEM, n = 3
independent determinations on each of 17 tumor and normal samples.
*Significant difference in each row at p < 0.05.
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enzyme in tissue are dependent on their environment. A
few studies have been done which provide sufficient evi-
dence of the alterations of kinetic properties of glycolytic
enzymes in cancer cells. LDH is a key enzyme of aerobic
glycolysis and attention has been paid to its kinetic
parameters in cancer cell lines in recent years [19,20].
Those studies have come across an important problem;
the tumor microenvironment has very heterogeneous
oxygen pressure, pH and other metabolites [21] whereas
the nature and importanceof the tumor microenviron-
ment has been masked owing to the use of tissue culture
conditions in which pH is normal without any fluctu-
ation, also oxygen and nutrients are always in excess.
This study was undertaken to compare the kinetic pa-
rameters of LDH in cancerous and normal tissues, with
focus on the fact that enzyme kinetic parameters are
dependent on their environment-involved enzyme. Our
current study has shown the C-LDH in forward reaction
has higher Vmax compared to Normal N-LDH but the
S0.5 of LDH between two tissues was not different. Ele-
vation of C-LDH Vmax, with respect to its constant S0.5,
can be due to increasein the total concentration of
enzyme in tumor tissue. Higher Vmax of C-LDH with
respect to pyruvate and NADH showed significantlyFigure 4 Lineweaver-Burk plots of LDH in partial purified breast canc
0.5-9.5 mM in reverse reaction. Data are presented as means ± SEM, n =increased lactate and NAD+ production and increased
pyruvate and NADH consumption. Three lines of evi-
dence can explain our findings. Firstly, cancer cells require
further levels of NAD+ for a continuing high glycolysis
rate [4] and high activity of LDH in forward reaction sup-
plies this requirement. Secondly, a high glycolysis rate in
tumor cells increases the level of NADH. The increasing
of NADH stimulates release of membrane bound LDH
(A4) and more conversion of NADH to NAD+ with con-
comitant consumption of pyruvate A4 isoenzyme activity
that catalyzes forward reaction will be increased in a meta-
bolic environment containing low oxygen supply and
ample pyruvate [22]. The two features exist in tumors, de-
pressed supply of oxygen occurs in tumor microenviron-
ment because blood vessels in tumors are often highly
abnormal [23,24], also high glycolysis rate in cancer cells
produces higher pyruvate level [25]. Our observations are
consistent with the above clarification; the activity of LDH
in forward reaction is higher in tumors than normal
tissues. In addition, reducing the level of pyruvate by
LDH in tumor tissues may assist cancer cells to main-
tain excessive growth and proliferation and may inhibit
cancer cell death. To confirm this hypothesis Thangar-
aju et al. has shown that pyruvate prevents cell growth
and proliferation by inhibition of histone deacetylase
activity [26]. High LDH activity in forward reaction by
altering pyruvate could eliminate the effect of pyruvate
on cancer cell growth.
LDH in reverse reaction converts lactate to pyruvate
with concomitant generation of NAD+ from NADH.
Our results demonstrated that C-LDH had higher Km for
both lactate and NAD+ when compared with N-LDH.
Contrary to our data, Debari et al. and Pizzuto et al. have
shown that Km lactate and Km NAD
+ were not different in
PC3 and HEP G2 cell lines in relation to normal cells.
The difference between our data and that reported
by other researchers may be related to the cultureer tissues (n =17) for (a) Lactate: 10–325 mM and (b) NAD+:
3 independent determinations on separate enzyme samples.
Figure 5 Lineweaver-Burk plots of LDH in partial purified breast normal tissues (n =17) for (a) Lactate: 5–110 mM and (b) NAD+:
0.25-8.5 mM in reverse reactions. Data are presented as means ± SEM, n = 3 independent determinations on separate enzyme samples.
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and proliferation, whereas the microenvironment of
tumor tissue has various limitations that stimulates cancer
cells to change their metabolism for persistent living and
proliferation [21,27].
Higher Km lactate and NAD
+ means the C-LDH has a
lower affinity for lactate and NAD+ to catalyze reverse
reaction in tumor tissues, in other words, cancer cells
resist converting lactate to pyruvate. This could be re-
lated to the key role of lactate in tumors. It has been
shown that lactate contributes to the immune escape of
cancer cells by inhibition of monocytes and dendritic
cells differentiation and also by reduction of cytokine re-
lease from dendritic and cytotoxic T cells. In addition,
the extrusion of high amount of lactate produced by aer-
obic glycolysis to the extracellular space could inhibit
the lactate secretion from immune cells due to change
in intra- to extracellular lactate balance. These changes
suppress cellular immunity in tumor tissue [28]. Another
possibility to explain our finding is the role of lactate in
tumor metastasis and angiogenesis. Lactate indirectly
enhances endothelial cell migration and angiogenesis
by stimulating vascular endothelial growth factor (VEGF)
production [29]. Lactate also increases the acidity of extra-
cellular pH, a condition that stimulates invasion and me-
tastasis of cancer cells [30]. The above mentioned traits of
lactate make it very valuable for cancer cells, becauseTable 6 The enzyme efficiency, represented as Vmax/Km
for LDH in partial purified tumor and normal breast
tissues
Tumor Normal
Vmax/Km with lactate (mU/mg/mM) 28.92 ± 1.3* 56.1 ± 2.4
Vmax/Km with NAD
+ (mU/mg/mM) 1294.94 ± 6.7* 2474 ± 8.1
Assays were conducted at 25°C and data are presented as means ± SEM, n = 3
independent determinations on each of 17 tumor and normal samples.
*Significant difference in each row at p < 0.05.according to Darwinian process, any traits that confer se-
lective advantages to one population arepreserved by the
population, therefore cancer cells should protect lactate
because of its benefits in tumorigenesis. Low LDH affinity
for lactate is one way of preserving lactate that is observe-
din the current study.
In addition, higher Km lactate in C-LDH shows the
C-LDH is less inhibited by high concentration of lac-
tate and higher lactate levels could be tolerated. This
feature of C-LDH may reflect one of the traits of the
tumor microenvironment, which is a higher lactate level.
Lactate level is significantly higher in tumors with meta-
static spread in comparison to malignancies in patient
without metastases [31,32]. Given the meaningful correl-
ation between lactate concentrations in tumors with meta-
static incidence, it can be concluded that the kinetic
parameters of LDH, with respect to lactate, should be
different in patients with metastases as one of the most
effective factors on an enzyme kinetic is the characteristic
of the environment that involves the enzyme.
The lower affinity of LDH for reverse reaction in tu-
mors compared with normal tissues was emphasized by
calculating the C-LDH and N-LDH efficiencies [33]. Our
results showed that LDH efficiency was higher for lactate
and NAD+ in normal tissues compared to tumors, which
means that normal cells have more affinity to lactate in re-
lation to tumor tissue which is consistent with the above
mentioned explanations.
Our results demonstrated that Ea of reverse reaction
was higher in tumors than that in normal tissues. This
finding provides novel thermodynamic evidence about
the inappropriate application of reverse reaction in
tumor cells. In general, the higher values of Km and Ea
and lower enzyme efficiency for tumor LDH in reverse
reaction showed cancer cells resist the conversion of lac-
tate to pyruvate. It is important to note that substrate
preference for reverse reaction by C-LDH and N-LDH
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ing the tumorigenesis. Further investigation is needed to
detect the posttranslational modification of LDH in can-
cer tissue and its effect on LDH structure and kinetic
parameters.
Conclusions
The results demonstrated that C-LDH has high affinity
to produce lactate in forward reaction while it has low
tendency to produce pyruvate in reverse reaction. Most
studies have suggested inhibiting LDH activity in forward
reaction [34] as one possible targeted therapy because the
activity and expression of LDH in forward reaction is
higher in cancer cells than normal cells. The current study
showed for the first time that there is another possible ap-
proach to confront LDH effectiveness in cancer cells: if
the affinity of LDH for lactate and NAD+can be increased,
lactate is converted to pyruvate at higher rate and lactate
dependent tumor growth and proliferation can be abol-
ished. Further investigation is needed to confirm this hy-
pothesis. In addition, the correlation between the kinetic
parameters of LDH and the incidence of metastasis should
be surveyed in more numbers of breast cancer patients.
Finally, various enzymes kinetic parameters of different
cancer cell lines should be investigated in culture condi-
tions in which both oxygen and nutrients are restricted,
similar to tumor microenvironment.
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